MedTrace Logo

Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults

NCT02496520 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-02-21

No results posted yet for this study

Summary

Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with autologous dendritic cells pulsed with tumor lysate) in patients affected of metastatic or relapsed sarcomas or (Central Nervous System) CNS tumors.

Conditions

  • Sarcoma
  • Central Nervous System Tumor

Interventions

BIOLOGICAL

dendritic cells

vaccines with dendritic cells pulsed with tumor lysate

PROCEDURE

Surgery as needed by the patient´s tumor and stage

DRUG

Chemotherapy as needed by the patient´s tumor and stage

RADIATION

Radiation therapy as needed by the patient´s tumor and stage

Sponsors & Collaborators

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Ana Patiño-García, PhD · CUN

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-09-16
Completion
2019-05-27

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02496520 on ClinicalTrials.gov